Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Lifelong immunoglobulin replacement is the standard, expensive therapy for severe primary antibody deficiencies. This treatment can be administrated either by intravenous immunoglobulin (IVIG) or subcutaneous infusions (SCIG) and delivered at home or in an out-patient setting. This study aims to determine whether SCIG is cost-effective compared with IVIG from a French social insurance perspective. Because both methods of administration provide similar efficacies, a cost-minimization analysis was performed. First, costs were calculated through a simulation testing different hypothesis on costs drivers. Secondly, costs were estimated on the basis of field data collected by a questionnaire completed by a population of patients suffering from agammaglobulinaemia and hyper-immunoglobulin (Ig)M syndrome. Patients' satisfaction was also documented. Results of the simulation showed that direct medical costs ranged from €19 484 for home-based IVIG to €25 583 for hospital-based IVIG, with home-based SCIG in between at €24 952 per year. Estimations made from field data were found to be different, with significantly higher costs for IVIG. This result was explained mainly by a higher immunoglobulin mean dose prescribed for IVIG. While the theoretical model showed very little difference between SCIG and hospital-based IVIG costs, SCIG appears to be 25% less expensive with field data because of lower doses used in SCIG patients. The reality of the dose difference between both routes of administration needs to be confirmed by further and more specific studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Cited by
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Abolhassani, H., Sadaghiani, M. S., Aghamohammadi, A., Ochs, H. D., & Rezaei, N. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9720-1 · Cited by 185
“Although home-based IVIg may be, in theory, the cheapest method of immunoglobulin therapy [38], in practice most intravenous administrations require outpatient settings and periodic hospital visits resulting in missed school or work days, the use of medical resources and loss of family time (Table IV, 10 articles, 238…”
BackgroundInfluentialSubcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review
Lingman-Framme, J., & Fasth, A. (2013) · Drugs · doi:10.1007/s40265-013-0094-3 · Cited by 71
Metadata
- Authors
- Beauté, J., Levy, P., Millet, V, Debré, M., Dudoit, Y., Le Mignot, L., Tajahmady, A., Thomas, C., Suarez, F., Pellier, I., Hermine, O., Aladjidi, N., Mahlaoui, N., & Fischer, A.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-16
- Volume
- 160
- Issue
- 2
- Pages
- 240-245
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1558642022
- Cited by
- 69
- References
- 1
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. https://app.cochat.ai/papers/10.1111/j.1365-2249.2009.04079.x
- The paper
- Beauté, J., Levy, P., Millet, V, Debré, M., Dudoit, Y., Le Mignot, L., Tajahmady, A., Thomas, C., Suarez, F., Pellier, I., Hermine, O., Aladjidi, N., Mahlaoui, N., & Fischer, A. (2010). Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clinical and Experimental Immunology. https://doi.org/10.1111/j.1365-2249.2009.04079.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.